PGEN vs SOPH: fair value comparison
Precigen, Inc. and SOPHiA GENETICS SA · Updated 2026-10-19
PGEN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. SOPH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PGEN currently ranks higher by quality score.
| PGEN | SOPH | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $6.38 | $6.73 |
| 12-month range | $3.10–$8.56 | $3.89–$8.92 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #159 of 301 Healthcare | #160 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | High | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | — | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: PGEN fair value analysis · SOPH fair value analysis